BioSpace News Archive

Imvax, Inc., a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, today announced the completion of enrollment in its randomized, multicenter, double-blind, placebo-controlled Phase 2b clinical trial of IGV-001 in patients with newly diagnosed glioblastoma (ndGBM).

Temple Street Biotech is proud to announce the initiation of a pioneering therapeutic antibody targeting prion protein for the treatment of Alzheimer’s disease.

LeMaitre Vascular, Inc. announced that George W. LeMaitre, Chairman & CEO, will present at the 2024 Jefferies Global Healthcare Conference on Thursday, June 6, 2024, at 11:00 AM ET at the Marriott Marquis in New York City.

Next Gen Diagnostics and a team at Vanderbilt University Medical Center announced the results of a study reporting that comparison of the whole genome sequence of bacterial pathogens obtained from surveillance of infants in a neonatal intensive care unit revealed substantial transmission of infection not detected by conventional infection control procedures.